Torrent Pharmaceuticals posted a 2.8% rise in consolidated net profit to Rs 330 crore on a 5.3% rise in net sales to Rs 2,120 crore in Q1 FY22 over Q1 FY21.
Consolidated profit before tax jumped 20.4% to Rs 484 crore in Q1 FY22 from Rs 402 crore reported in Q1 FY21. Consolidated EBITDA grew by 8% year on year to Rs 717 crore in Q1 FY22. EBITDA margin improved to 34% in Q1 FY22 from 32% in Q1 FY21.
The pharmaceutical company's R&D spends stood at Rs 125 crore in Q1 FY22 as compared to Rs 108 crore posted in Q1 FY21.
Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the country. The company has presence in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). It also has presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
Shares of Torrent Pharmaceuticals were down 2.46% at Rs 2,930 on BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app